Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

By S. Bolen, L. Feldman, J. Vassy, L. Wilson, H. Yeh, S. Marinopoulos, C. Wiley, E. Selvin, Renee F Wilson, E. Bass and 1 more. Annals of Internal Medicine, 2007

866 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/f9d4a5a892443384f7caa1c42315f330dd93404c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. R. Bergenstal
2. G. Umpierrez
3. K. Wolski
4. Ralph DeFronzo
5. V. Basevi

Citations in the corpus

• Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations (2011, background): “The Agency for Healthcare Research and Quality published its first systematic review on the comparative effectiveness and safety of oral hypoglycemic medications for type 2 diabetes in 2007 (11, 12).”
• Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. (2008, background): “However, the majority of recent analyses suggest a neutral effect for this class of agents on cardiovascular outcomes.(1,3) We compared the effects of these 2 widely used, but distinctly different, classes of oral hypoglycemic agents on the rate of progression of coronary atherosclerosis.”
• Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines (2011, background): “The biguanide metformin is the drug of first choice in adults with non-insulin-dependent diabetes mellitus, not controlled by diet and exercise [141, 142].”
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2012, background): “5%) [1, 69, 70], and generally lower for meglitinides, DPP-4 inhibitors, AGIs, colesevelam and bromocriptine (~0.”
• CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, background): “Side effects that have limited TZD use include weight gain, increased bone fracture risk in postmenopausal women and elderly men, and elevated risk for chronic edema or heart failure (108-111).”
• Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy (2008, neutral): “In addition, meta-analyses and reviews have summarised and compared the glucose-lowering effectiveness and other characteristics of the medications [35–37].”
• Association of an Intensive Lifestyle Intervention With Remission of Type 2 Diabetes (2012, neutral): “The ability to eliminate all diabetes medications while maintaining subdiabetic levels of fasting plasma glucose and HbA1c levels should considerably reduce medication costs, related adverse effects, risks of hypoglycemia, and hyperglycemic symptoms.(16,17) Prior studies of medication-based therapy ”
• Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. (2012, background): “Sulfonylureas are long-acting insulin secretagogues that can cause severe and prolonged hypoglycemia, particularly in the elderly, in patients with impaired renal function, and in those with poor nutritional intake (70).”